science

The Association between Mushroom Consumption and Mild Cognitive Impairment: A Community-Based Cross-Sectional Study in Singapore (2019)


We examined the cross-sectional association between mushroom intake and mild cognitive impairment (MCI) using data from 663 participants aged 60 and above from the Diet and Healthy Aging (DaHA) study in Singapore.


A Randomized, Double-Blind and Placebo-Controlled Study of a Ganoderma lucidum Polysaccharide Extract in Neurasthenia (2005)


Ganoderma lucidum has been widely used to treat various diseases, including cancer, diabetes, and neurasthenia in many Asian countries.


Improving Effects of the Mushroom Yamabushitake (Hericium erinaceus) on Mild Cognitive Impairment: A Double-blind Placebo-controlled Clinical Trial (2009)


A double-blind, parallel-group, placebo-controlled trial was conducted in Japanese men and women aged 50-80 years who were diagnosed with mild cognitive impairment using a cognitive function scale based on the revised Hasegawa Dementia Scale (HDS-R) to examine the effect of oral consumption of erinaceus erinaceus on improving cognitive impairment.


Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake (2010)


Hericium erinaceus, a well known edible mashroom, has numerous biological activities.


Improvement of cognitive functions by oral intake of Hericium erinaceus (2019)


Hericium erinaceus has been considered as a medicinal mushroom since ancient times, but the scientific evidence for its effect on human health remains uncertain.


A retrospective study of Ganoderma Lucidum Spore Powder for patients with epilepsy (2018)


This study firstly investigated the feasibility effect and safety of Ganoderma Lucidum Spore Powder (GLSP) for treating patients with epilepsy.


< 1 >